Trisenox

Trisenox is a brand name of arsenic trioxide, approved by the FDA in the following formulation(s):

TRISENOX (arsenic trioxide - injectable; injection)

• 
  Manufacturer: CEPHALON
  
  Approval date: September 25, 2000
  
  Strength(s): 1MG/ML ^[RLD]

Has a generic version of Trisenox been approved?

No. There is currently no therapeutically equivalent version of Trisenox available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Trisenox. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
  Patent 6,723,351
  Issued: April 20, 2004
  Inventor(s): Raymond P.; Warrell, Jr. & Pier Paolo; Pandolfi & Janice L.; Gabrilove
  Assignee(s): Memorial Sloan-Kettering Cancer Center
  The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
  
  Patent expiration dates:
  
  
  • November 10, 2018
    
    ✓ 
    Patent use: TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)
  
  



• 
  Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
  Patent 6,855,339
  Issued: February 15, 2005
  Inventor(s): Warrell, Jr.; Raymond P. & Pandolfi; Pier Paolo & Gabrilove; Janice L.
  Assignee(s): Memorial Sloan-Kettering Cancer Center
  The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
  
  Patent expiration dates:
  
  
  • November 10, 2018
    
    ✓ 
    Patent use: TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)
  
  



• 
  Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
  Patent 6,861,076
  Issued: March 1, 2005
  Inventor(s): Warrell, Jr.; Raymond P. & Pandolfi; Pier Paolo & Gabrilove; Janice L.
  Assignee(s): Memorial Sloan-Kettering Cancer Center
  The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
  
  Patent expiration dates:
  
  
  • November 10, 2018
    
    ✓ 
    Patent use: TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)
  
  



• 
  Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
  Patent 6,884,439
  Issued: April 26, 2005
  Inventor(s): Warrell, Jr.; Raymond P. & Pandolfi; Pier Paolo & Gabrilove; Janice L.
  Assignee(s): Memorial Sloan-Kettering Cancer Center
  The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
  
  Patent expiration dates:
  
  
  • November 10, 2018
    
    ✓ 
    Patent use: TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL)
  
  



• 
  Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
  Patent 6,982,096
  Issued: January 3, 2006
  Inventor(s): Warrell, Jr.; Raymond P. & Pandolfi; Pier Paolo & Gabrilove; Janice L.
  Assignee(s): Memorial Sloan-Kettering Cancer Center
  The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
  
  Patent expiration dates:
  
  
  • November 10, 2018
    
    ✓ 
    Patent use: TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL)
  
  

See also...

• Trisenox Consumer Information (Wolters Kluwer)
• Trisenox Consumer Information (Cerner Multum)
• Trisenox Advanced Consumer Information (Micromedex)
• Trisenox AHFS DI Monographs (ASHP)
• Arsenic Consumer Information (Wolters Kluwer)
• Arsenic trioxide Consumer Information (Cerner Multum)
• Arsenic trioxide Intravenous Advanced Consumer Information (Micromedex)
• Arsenic Trioxide AHFS DI Monographs (ASHP)